--- title: "BlossomHill Therapeutics files for IPO, plans Nasdaq listing" url: "https://aibio.space/news/blossomhill-therapeutics-files-ipo-plans-nasdaq-listing-blsm/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-07-17" section: "Financings" tickers: "NASDAQ:BLSM" source: "https://www.sec.gov/Archives/edgar/data/1839970/000119312526306506/d98958ds1.htm" summary: "BlossomHill's S-1 leaves the share count, the price range and the proceeds blank. The prospectus also says the auditor's report on the 2025 financial state" --- By the aibio.space news desk. Sources - [BlossomHill Therapeutics, Inc. S-1 (2026-07-17)](https://www.sec.gov/Archives/edgar/data/1839970/000119312526306506/d98958ds1.htm) [BLSM](https://aibio.space/companies/blossomhill-therapeutics/) 2026-07-17 # BlossomHill Therapeutics files for IPO, plans Nasdaq listing as BLSM Tickers [BLSM](https://aibio.space/companies/blossomhill-therapeutics/) BlossomHill's S-1 leaves the share count, the price range and the proceeds blank. The prospectus also says the auditor's report on the 2025 financial statements carries a going-concern paragraph. ## Key facts - **Company**: BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) - **News type**: Financings - **Primary source**: [BlossomHill Therapeutics, Inc. S-1 (2026-07-17)](https://www.sec.gov/Archives/edgar/data/1839970/000119312526306506/d98958ds1.htm) *A meeting room with a long table and a screen. CC0, via rawpixel. The picture shows the field, not the companies named.* ## What is still blank BlossomHill Therapeutics, Inc. filed a registration statement on Form S-1, with a preliminary prospectus dated July 16, 2026. The Delaware company has its principal executive offices at 10255 Science Center Drive in San Diego. It has applied to list its common stock on the Nasdaq Global Select Market under the symbol BLSM, and the offering depends on that approval. The cover leaves blank the number of shares, the expected price range and the net proceeds. The underwriters' option to purchase additional shares runs for 30 days, and its size is also blank. The cover names five underwriters in this order: J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital and H.C. Wainwright & Co. It does not say which firm leads the book. Cooley LLP and Latham & Watkins LLP are listed under "Copies to," but the filing does not say which firm acts for the company and which for the underwriters. The company plans to use the net proceeds, together with its existing cash, to advance BH-30643 and BH-30236 in clinical trials, to complete IND-enabling studies and start a Phase 1 trial of BH-501284, and for other research, capital expenditures and working capital. The filing also plans a reverse stock split of its common and preferred stock, but the ratio is blank. ## The company and its programs BlossomHill says it began operations in the summer of 2020, led by its scientific founder and chief executive, J. Jean Cui, Ph.D. The company says it has raised over $257 million from healthcare-focused investors since inception. Co-founder and executive chairman Y. Peter Li, Ph.D., MBA, and chief financial officer Jason Keyes, MBA, are named in the prospectus. The lead candidate, BH-30643, is an OMNI-EGFR inhibitor being tested in the SOLARA global Phase 1/2 trial in EGFR-mutant non-small cell lung cancer. The trial is enrolling dose expansion cohorts in patients who have and have not had prior TKI treatment, including a C797S resistance cohort. The company plans an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 about the recommended Phase 2 dose and a possible accelerated approval path. It estimates about 3,200 patients a year in the United States have C797S-driven resistance, and says no approved oral targeted therapy exists for them in the United States. The prospectus calls the BH-30643 efficacy data preliminary and refers readers to the business section for results. The summary itself gives no response rates. It does cite a 79% overall response rate for repotrectinib, a drug from Turning Point Therapeutics, which Dr. Cui co-founded. That figure comes from a different drug in ROS1-positive lung cancer, not from BH-30643. The second clinical program, BH-30236, is a CLK inhibitor in a Phase 1 trial in relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes. The trial is still in dose escalation, and the company expects updated safety and efficacy data in the first half of 2027. The preclinical candidate, BH-501284, targets KRAS. The company says its tumor regression came in mouse models, and it plans to submit an IND in the first quarter of 2027. ## Cash, losses and the auditor The auditor's report on the financial statements for the year ended December 31, 2025 included a going-concern explanatory paragraph. The company says it has concluded there is substantial doubt about its ability to continue as a going concern. It also says that if it cannot raise capital when needed, its business, financial condition and results of operations will be materially affected. As of March 31, 2026 the company had cash and cash equivalents of $116.0 million and an accumulated deficit of $156.0 million. Management says there is uncertainty whether its present capital resources will fund planned operations beyond twelve months from the issuance date of the financial statements. The audited statements show a net loss of $60,555 thousand for 2025, against $30,695 thousand for 2024, with research and development expense of $56,138 thousand in 2025 against $31,810 thousand in 2024. The prospectus says the share count of 99,653,723 as of March 31, 2026 is set after two steps: the automatic conversion of the convertible preferred stock into 85,552,612 common shares at closing, and the issue of 1,711,033 shares on option exercises after March 31, 2026. Some of those option shares remain subject to a right of repurchase. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story BLSM BlossomHill Therapeutics, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/blossomhill-therapeutics-files-ipo-plans-nasdaq-listing-blsm/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BlossomHill Therapeutics files for IPO, plans Nasdaq listing", 2026-07-17, https://aibio.space/news/blossomhill-therapeutics-files-ipo-plans-nasdaq-listing-blsm/